Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia.
作者信息
Kantarjian Hagop, Thomas Deborah, Wayne Alan S, O'Brien Susan
机构信息
Leukemia Department, MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA.
出版信息
J Clin Oncol. 2012 Nov 1;30(31):3876-83. doi: 10.1200/JCO.2012.41.6768. Epub 2012 Aug 13.
Abstract
摘要
相似文献
1
Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia.基于单克隆抗体的疗法：急性淋巴细胞白血病治疗的新曙光。
J Clin Oncol. 2012 Nov 1;30(31):3876-83. doi: 10.1200/JCO.2012.41.6768. Epub 2012 Aug 13.
2
Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.利妥昔单抗单克隆抗体治疗急性淋巴细胞白血病。
Hematol Oncol Clin North Am. 2009 Oct;23(5):949-71, v. doi: 10.1016/j.hoc.2009.07.005.
3
New antibodies for acute lymphocytic leukemia.用于急性淋巴细胞白血病的新型抗体。
Clin Adv Hematol Oncol. 2014 Aug;12(8):547-9.
4
Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.利妥昔单抗诱发弥漫性大B细胞淋巴瘤急性肿瘤溶解综合征
Int J Hematol. 2005 Nov;82(4):312-4. doi: 10.1532/IJH97.NA0504.
5
Novel targets for treatment of adult acute lymphocytic leukemia.治疗成人急性淋巴细胞白血病的新靶点。
Curr Hematol Malig Rep. 2010 Oct;5(4):207-12. doi: 10.1007/s11899-010-0064-8.
6
Monoclonal antibodies in adult acute lymphoblastic leukemia.成人急性淋巴细胞白血病中的单克隆抗体
Hematology. 2012 Apr;17 Suppl 1:S52-4. doi: 10.1179/102453312X13336169155538.
7
Rituximab as therapy for acute lymphoblastic leukemia.利妥昔单抗作为急性淋巴细胞白血病的治疗方法。
Clin Adv Hematol Oncol. 2010 Mar;8(3):168-71.
8
Rituximab with interleukin-2 after autologous bone marrow transplantation for acute lymphocytic leukemia in second remission.利妥昔单抗联合白细胞介素-2用于急性淋巴细胞白血病二次缓解期自体骨髓移植后
Med Pediatr Oncol. 2002 Apr;38(4):300-1. doi: 10.1002/mpo.1335.
9
Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy.鞘内注射利妥昔单抗治疗中枢神经系统复发且对传统治疗耐药的急性淋巴细胞白血病患者的疗效。
Br J Haematol. 2009 Mar;144(5):794-5. doi: 10.1111/j.1365-2141.2008.07497.x. Epub 2008 Nov 19.
10
[Proteins in haematology].[血液学中的蛋白质]
Ther Umsch. 2011 Nov;68(11):610-7. doi: 10.1024/0040-5930/a000221.
引用本文的文献
1
Nelarabine-combined chemotherapy improves outcome of T-cell acute lymphoblastic leukemia but shows more severe neurotoxicity: JALSG T-ALL213-O.奈拉滨联合化疗可改善T细胞急性淋巴细胞白血病的预后，但显示出更严重的神经毒性：日本成人白血病研究组T-ALL213-O研究。
Cancer Sci. 2025 Feb;116(2):453-461. doi: 10.1111/cas.16405. Epub 2024 Nov 21.
2
Rational Design of Highly Potent and Selective Covalent MAP2K7 Inhibitors.高效且选择性共价MAP2K7抑制剂的合理设计
ACS Med Chem Lett. 2023 Apr 17;14(5):606-613. doi: 10.1021/acsmedchemlett.3c00029. eCollection 2023 May 11.
3
Clathrin light chain-conjugated drug delivery for cancer.用于癌症治疗的网格蛋白轻链偶联药物递送
Bioeng Transl Med. 2022 Nov 28;8(1):e10273. doi: 10.1002/btm2.10273. eCollection 2023 Jan.
4
The cure of leukemia through the optimist's prism.通过乐观主义者的视角看待白血病的治愈。
Cancer. 2022 Jan 15;128(2):240-259. doi: 10.1002/cncr.33933. Epub 2021 Oct 6.
5
Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia.单细胞基因表达分析揭示急性髓系白血病白血病干细胞隔间中具有不同自我更新和增殖能力的亚群。
Cancer Res. 2020 Feb 1;80(3):458-470. doi: 10.1158/0008-5472.CAN-18-2932. Epub 2019 Nov 29.
6
Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer.急性白血病免疫治疗的当前进展：抗体、嵌合抗原受体、免疫检查点及自然杀伤细胞概述
Front Oncol. 2019 Sep 19;9:917. doi: 10.3389/fonc.2019.00917. eCollection 2019.
7
Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.奥英妥珠单抗治疗复发或难治性B细胞急性淋巴细胞白血病
J Adv Pract Oncol. 2018 Sep-Oct;9(6):670-676. Epub 2018 Sep 1.
8
Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma.白血病和淋巴瘤中的自噬治疗调节。
Cells. 2019 Jan 30;8(2):103. doi: 10.3390/cells8020103.
9
Adult Acute Lymphoblastic Leukemia: Limitations of Intensification of Therapy in a Developing Country.成人急性淋巴细胞白血病：发展中国家强化治疗的局限性
J Glob Oncol. 2018 Sep;4:1-12. doi: 10.1200/JGO.17.00014.
10
Treatment of Older Patients with Acute Lymphoblastic Leukaemia.老年急性淋巴细胞白血病患者的治疗
Drugs Aging. 2018 Jan;35(1):11-26. doi: 10.1007/s40266-017-0503-5.
本文引用的文献
1
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.抗CD22免疫毒素莫克妥昔单抗帕苏妥昔用于儿童急性淋巴细胞白血病的1期研究。
Blood. 2017 Oct 5;130(14):1620-1627. doi: 10.1182/blood-2017-02-749101. Epub 2017 Aug 9.
2
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2.复发急性淋巴细胞白血病（ALL）中再次使用依鲁替尼化疗免疫治疗：来自儿童肿瘤学组（COG）ADVL04P2 研究的 II 期结果。
Pediatr Blood Cancer. 2015 Jul;62(7):1171-5. doi: 10.1002/pbc.25454. Epub 2015 Mar 2.
3
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.美罗华联合短程、高强度化疗联合粒细胞集落刺激因子支持治疗伯基特或侵袭性淋巴瘤的疗效改善：癌症和白血病组 B 研究 10002。
Br J Haematol. 2014 Apr;165(1):102-11. doi: 10.1111/bjh.12736. Epub 2014 Jan 15.
4
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.一项抗 CD19 美登素免疫偶联物 SAR3419 的 I 期多剂量递增研究，该药物通过静脉输注给药，每 3 周给药一次，用于治疗复发/难治性 B 细胞淋巴瘤患者。
J Clin Oncol. 2012 Aug 1;30(22):2776-82. doi: 10.1200/JCO.2011.39.4403. Epub 2012 Jul 2.
5
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.急性淋巴细胞白血病伴分子学复发的成年患者预后不良，是干细胞移植和靶向治疗的候选人群。
Blood. 2012 Aug 30;120(9):1868-76. doi: 10.1182/blood-2011-09-377713. Epub 2012 Mar 22.
6
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.依妥珠单抗奥滨尤妥珠单抗，一种抗 CD22-卡利霉素偶联物，用于治疗难治和复发的急性淋巴细胞白血病：一项 2 期研究。
Lancet Oncol. 2012 Apr;13(4):403-11. doi: 10.1016/S1470-2045(11)70386-2. Epub 2012 Feb 21.
7
SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.SAR3419：一种抗 CD19-美登素免疫偶联物，用于治疗 B 细胞恶性肿瘤。
Clin Cancer Res. 2011 Oct 15;17(20):6448-58. doi: 10.1158/1078-0432.CCR-11-0485.
8
Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.加利车霉素衍生物抗体药物偶联物：吉妥珠单抗奥佐米星和伊妥珠单抗奥佐米星。
Clin Cancer Res. 2011 Oct 15;17(20):6417-27. doi: 10.1158/1078-0432.CCR-11-0486.
9
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.抗体融合蛋白：抗 CD22 重组免疫毒素 moxetumomab pasudotox。
Clin Cancer Res. 2011 Oct 15;17(20):6398-405. doi: 10.1158/1078-0432.CCR-11-0487.
10
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.免疫毒素和抗体药物偶联物治疗血液系统恶性肿瘤。
Cancer Res. 2011 Oct 15;71(20):6300-9. doi: 10.1158/0008-5472.CAN-11-1374.
Zotero 插件